These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28201868)

  • 1. Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.
    Fouladi F; Steffen KJ; Mallik S
    Bioconjug Chem; 2017 Apr; 28(4):857-868. PubMed ID: 28201868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic Acid-Based pH-Sensitive Polymer-Modified Liposomes for Cell-Specific Intracellular Drug Delivery Systems.
    Miyazaki M; Yuba E; Hayashi H; Harada A; Kono K
    Bioconjug Chem; 2018 Jan; 29(1):44-55. PubMed ID: 29183110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-responsive liposomes for controlled drug release.
    Wei Y; Lv J; Zhu S; Wang S; Su J; Xu C
    Drug Discov Today; 2024 Jul; 29(7):104014. PubMed ID: 38705509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
    Andresen TL; Jensen SS; Jørgensen K
    Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties.
    Linderoth L; Peters GH; Madsen R; Andresen TL
    Angew Chem Int Ed Engl; 2009; 48(10):1823-6. PubMed ID: 19173369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid prodrug nanocarriers in cancer therapy.
    Mura S; Bui DT; Couvreur P; Nicolas J
    J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional liposomes in the cancer-targeted drug delivery.
    Tila D; Ghasemi S; Yazdani-Arazi SN; Ghanbarzadeh S
    J Biomater Appl; 2015 Jul; 30(1):3-16. PubMed ID: 25823898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Conjugates Using Different Dynamic Covalent Bonds and their Application in Cancer Therapy.
    Theodosis-Nobelos P; Charalambous D; Triantis C; Rikkou-Kalourkoti M
    Curr Drug Deliv; 2020; 17(7):542-557. PubMed ID: 32384029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of stimuli-responsive polymers as anticancer drug delivery systems.
    Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z
    Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticles as delivery carriers for anticancer prodrugs.
    Fang JY; Al-Suwayeh SA
    Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
    Linderoth L; Fristrup P; Hansen M; Melander F; Madsen R; Andresen TL; Peters GH
    J Am Chem Soc; 2009 Sep; 131(34):12193-200. PubMed ID: 19663381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
    Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
    Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A General Approach to Enzyme-Responsive Liposomes.
    Lou J; Best MD
    Chemistry; 2020 Jul; 26(39):8597-8607. PubMed ID: 32301193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colloidal systems for tumor targeting.
    Storm G; Crommelin DJ
    Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospholipidic Colchicinoids as Promising Prodrugs Incorporated into Enzyme-Responsive Liposomes: Chemical, Biophysical, and Enzymological Aspects.
    Shchegravina ES; Tretiakova DS; Alekseeva AS; Galimzyanov TR; Utkin YN; Ermakov YA; Svirshchevskaya EV; Negrebetsky VV; Karpechenko NY; Chernikov VP; Onishchenko NR; Vodovozova EL; Fedorov AY; Boldyrev IA
    Bioconjug Chem; 2019 Apr; 30(4):1098-1113. PubMed ID: 30817133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial-temporal event adaptive characteristics of nanocarrier drug delivery in cancer therapy.
    Kong M; Park H; Cheng X; Chen X
    J Control Release; 2013 Nov; 172(1):281-291. PubMed ID: 24004884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
    Luo C; Sun J; Sun B; He Z
    Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional nanomicellar systems for delivering anticancer drugs.
    Chen YC; Lo CL; Hsiue GH
    J Biomed Mater Res A; 2014 Jun; 102(6):2024-38. PubMed ID: 23828850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.